BioNTech Halts Phase 2 Trial for mRNA Cancer Immunotherapy

BioNTech has ended its Phase 2 clinical trial for autogene cevumeran, an individualized mRNA cancer immunotherapy for colorectal cancer. The decision followed a Data Safety Monitoring Board review that found a numerical imbalance in overall survival, indicating the trial was unlikely to achieve its efficacy goals. No new safety concerns were reported.